Agreed. The more I read about it the more quietly confident I...

Agreed. The more I read about it the more quietly confident I feel about a positive result though.

The lead investigator, Ron Grunstein, is the most published sleep researcher in Australia; the Woolcock Institute is considered one of the top sleep institutes in the world; the formulation they’re using has substantially outperformed the bioavailability of Epidiolex in PK trials; and they’re using a dosage and trial design that has been supported by prior research results. My concerns are that we haven’t sufficiently differentiated ourselves from other trials that have failed, but management seem confident our design is superior. My concerns are also somewhat mitigated by the fact that there is a world class team behind the trial who know far more than any of us and have done this enough times to know the sorts of things that maximise the chances of trial success.

Psychological distress and anxiety is also well supported by data which is another indication I’m interested in for CBD and I think it is a secondary end point in our trial (Andrew Huberman has a podcast that talks through much of the ongoing trials / evidence for reference). Companies like EMD are also playing in this space but I think mixed with the right marketing our first mover advantage will be huge.

Plenty of upside here if it all goes well, even before considering the commercialisation of Aquaphase.